Project Grant R37CA292807
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$641K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The federal Project Grant award of $1,224,997.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Cold Spring Harbor Laboratory (CSHL) to conduct research aimed at "ENHANCING IMMUNITY IN COLORECTAL CANCER LIVER METASTASES." This grant, with a performance period from August 1, 2024 to July 31, 2028, will allow CSHL, a renowned non-profit research institution, to leverage its expertise in cancer biology, genomics,...
This $406,611 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to identify the role and signaling mechanisms of GPR56 in colorectal cancer disease progression and resistance, and to develop and evaluate unique GPR56-targeted antibody-drug conjugates (ADCs) and combination therapies for improved colorectal cancer treatment.
The key objectives are: 1) characterizing the role and signaling of GPR56 in colorectal cancer stem cells...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research organization in New York. The goal of this 2-year award, effective March 1, 2025, is to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic colorectal cancer lesions using patient-derived organoid models. The research aims to identify...
This Project Grant award of $145,336 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate metabolic reprogramming of hepatic macrophages as a therapeutic strategy for overcoming immune evasion in "immune-desert" liver tumors.
The two-year project aims to determine how deletion of the metabolic regulator TSC1 in hepatic macrophages can enable...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $205,700 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on targeting chromosomal instability in the evolution of resistance to matched therapies against colorectal cancer.
The research aims to evaluate how intrinsic tumor features modulate the development of resistance to targeted cancer therapies and to test a novel...
This $610,890 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to evaluate the clinical efficacy and underlying mechanisms of a novel combination immunotherapy approach for intrahepatic cholangiocarcinoma (ICCA), an aggressive form of liver cancer. The award supports a Phase II clinical study that will combine external beam radiotherapy, autologous dendritic cell injections, and dual PD-L1/TIGIT checkpoint inhibition. The study will...
This National Cancer Institute (NCI) Project Grant Award under the Cancer Treatment Research Program (CFDA 93.395) provides $633,355 to Northwestern University to conduct research on sustaining the metabolic fitness of effector CD8+ T cells for enhanced anti-tumor immunity. The research aims to define the metabolic and cellular effects of sustaining the glutathione-glutathione peroxidase 4 (GSH-GPX4) axis while inhibiting the adenosine A2A receptor (A2AR) signaling pathway in effector T...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,880 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to overcome treatment resistance in solid tumors, such as melanoma, by engineering CD4+ T cells to express IL-12 and IL-18 to activate innate immune cells within the tumor microenvironment. The award...
This $496,391 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of North Carolina at Chapel Hill (UNC-CH) to investigate how the solid tumor microenvironment impacts the metabolic function and antitumor activity of tumor-infiltrating CD8+ T cells. The research aims to determine whether the enzyme acetyl-CoA carboxylase (ACC) serves as a key metabolic switch that restricts the ability of CD8+ T cells to...